UroToday19h
ASCO 2024: Comparison of Outcomes with Docetaxel or ARPI Combination Therapy for mHSPC by Volume of Disease
(UroToday.com) The 2024 American Society of Clinical Oncology (ASCO) annual meeting featured a session on prostate cancer, and a presentation by Dr. Martin Schoen discussing a comparison of outcomes ...
UroToday2d
Friends of Israel Urological Symposium- Conference Coverage
is honored to present coverage from the 4th Friends of Israel Urological Symposium (FOIU) held in Tel Aviv, Israel. The 2018 Symposium creates an unparalleled opportunity for local and international ...
UroToday5d
The Optimal Treatment for Gleason Score 9-10 Prostate Cancer
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
UroToday6d
AUA 2024: Can I use Markers and Imaging to Avoid Local Consolidation for Patient who has cT0 stage after Neoadjuvant Chemo or IO?
(UroToday.com) The 2024 American Urological Association (AUA) annual meeting held in San Antonio, TX between May 3 and May 6, 2024, was host to the AUA-IBCG Bladder Cancer Forum. Drs. Stephen Williams ...
UroToday6d
Efficacy and Safety of Artificial Urinary Sphincters in Female Patients With Stress Urinary Incontinence: A Systematic Review and Meta-Analysis.
Stress urinary incontinence (SUI) significantly affects the quality of life in women, causing social, psychological, and physical distress. While artificial urinary sphincter (AUS) implantation is a ...
UroToday6d
Gut Microbiota Dysbiosis Accelerates Prostate Cancer Progression Through Increased LPCAT1 Expression and Enhanced DNA Repair Pathways.
Gut microbiota dysbiosis is related to cancer development and progression. Our previous study showed that Ruminococcus was more abundant in CRPC (Castration-resistant prostate cancer) than HSPC ...
UroToday6d
Treatment approaches in advanced penile cancer: targeted therapies and immunotherapy.
Penile cancer is a rare genitourinary malignancy which can be treated with surgery or radiation for localized disease, but often requires systemic treatment with chemotherapy for recurrent or ...
UroToday6d
PARP inhibitor-based treatment in metastatic, castration-resistant prostate cancer (mCRPC): A systematic review and meta-analysis.
We present a systematic review and meta-analysis of randomized clinical trials (RCTs) with PARPi either as monotherapy or in combination with an androgen receptor-targeted agent (ARTA) in first- and ...
UroToday6d
Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis.
The microbiota comprises the microorganisms that live in close contact with the host, with mutual benefit for both counterparts. The contribution of the gut microbiota to the emergence of ...
UroToday6d
Evidence-Based Framework for Surgical Irrigation Fluid Stewardship and Endoscopic Case Prioritization During Fluid Shortages.
The US supply disruption of surgical irrigation fluids in September 2024 prompted the need for fluid conservation and potential deferral of urology procedures. We characterized fluid use in common ...
UroToday6d
The gut microbiota associated with high-Gleason prostate cancer.
We have found that intestinal bacteria and their metabolites, short-chain fatty acids (SCFAs), promote cancer growth in prostate cancer (PCa) mouse models. To clarify the association between gut ...
UroToday6d
Predictive role of ABC transporters in the efficacy of enfortumab vedotin for urothelial carcinoma.
To evaluate the correlation between ATP-binding cassette (ABC) transporter expression and therapeutic efficacy of enfortumab vedotin (EV), an antibody-drug conjugate targeting Nectin-4, in urothelial ...